drugset / Trial / NCT06116591
A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of the study is to learn about the effects of a monovalent (single component) pneumococcal conjugate candidate (mPnC candidate) when given to toddlers between 11 and 15 months of age. All participants in this study will receive 2 doses of either mPnC candidate or mPnC control at the clinic approximately 8 weeks apart. All participants will also receive their third (toddler) dose of PCV10 at Visit 1.
Timeline
- Start
- 2023-11-08
- Primary completion
- 2024-05-27
- Completion
- 2024-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mPnC candidate | Vaccine | — | — |
| Comparator | mPnC control | Vaccine | — | — |
Indications
No indication recorded.